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Abstract		
Purpose:	to	evaluate	the	efficacy	and	safety	of	atropine	0.01%	in	slowing	myopia	progression	in	
European	pediatric	patients.	
Methods:	retrospective,	medical	records	review	study.	Medical	charts	of	pediatric	patients	with	a	
myopia	progression	>	0.5	D/year	treated	with	atropine	0.01%	for	at	least	1	year	were	included.	
Patients	receive	a	complete	ophthalmic	examination	before	and	12	months	after	initiation	of	
atropine	treatment.	A	group	of	myopic	untreated	children	serves	as	a	control	group.	
The	rate	of	myopia	progression	at	baseline	and	12	months	after	treatment	with	atropine	was	
evaluated.	The	rate	of	myopia	progression	in	treated	and	untreated	patients	was	also	compared.	
Adverse	events	were	recorded.			
Results:	medical	records	of	52	treated	and	50	control	subjects	were	analyzed.		
In	the	atropine	group,	the	mean	rate	of	myopia	progression	after	12	months	of	treatment	(-0.54	±	
0.61	D	)	was	significantly	slower	compared	to	the	baseline	progression	(-1.20	±	0.64	D;	P	<	.0001)	
and	to	the	progression	in	the	control	group		(-1.09	±	0.64;	P	<	.0001).	
The	responders	patients	were	41/52	(79%),	whereas	11/52	patients	(21%)	showed	a	progression	>	
0.50	D	despite	treatment.	The	only	adverse	event	was	temporary	photophobia	in	5	patients	
(9.6%),	severe	adverse	events	were	not	reported,	and	none	of	the	patients	discontinued	the	
treatment.	
Conclusion:			
Low-dose	atropine	significantly	slowed	the	rate	of	myopia	progression	in	European	pediatric	
patients	with	a	favorable	safety	profile.		
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Efficacy	of	atropine	0.01%	for	the	treatment	of	childhood	myopia	in	European	patients		
	
Myopia	is	considered	a	significant	public	health	concern	nowadays	and	has	been	included	among	
the	priorities	in	the	‘Vision	2020’	initiative	by	the	World	Health	Organization’s	Global	Initiative	for	
the	Elimination	of	Avoidable	Blindness	(Pararajasegaram	1999).		
The	prevalence	of	myopia	is	rapidly	growing	worldwide.	Recent	reviews	estimated	that	2.5	billion	
people	will	have	myopia	by	2020	(Morgan	et	al.	2012)	and	approximately	half	of	the	world	
population	will	be	myopic	by	2050	with	10%	of	them	affected	by	high	myopia	(Holden	et	al.	2016).	
The	prevalence	of	myopia	is	growing	in	both	Asian	and	West	countries	(Tay	et	al.	1992;	Vitale	et	al.	
2009).	In	the	United	States,	myopia	affects	approximately	40%	of	the	adult	populations	(Vitale	et	
al.	2009)	and	a	rising	prevalence	has	been	reported	in	European	area	(Williams	et	al.	2015)	and	
even	in	Australia,	a	low	myopia	prevalence	area,	where	a	four-fold	increase	in	the	prevalence	of	
myopia	was	observed	throughout	the	past	century	(McCarty	&	Taylor	2000).	
In	Asian	countries,	the	prevalence	of	myopia	has	rapidly	grown	in	the	past	decades,	and	today	in	
the	urban	areas	up	to	90%	of	high-school	students	are	affected	by	myopia	and	up	to	20%	are	
affected	by	high	myopia	(Lin	et	al.	2004).	In	addition	to	the	epidemiologic	and	social	burden	
myopia	is	a	known	risk	factor	for	a	sigh-threating	condition	as	retinal	detachment,	myopic	macular	
degeneration,	and	glaucoma	(Pan	et	al.	2012;	Mitchell	et	al.	1999).	Several	treatments	have	been	
investigated	for	the	control	of	myopia	including	the	topical	use	of	atropine.	Although	in	the	past	
decades	clinical	studies	investigated	the	role	of	atropine	in	controlling	myopia	(Kelly	et	al.	1975;	
Bedrossian	1971;	Yen	et	al.	1989),	was	not	until	the	Atropine	for	the	Treatment	of	childhood	
Myopia	(ATOM)	studies	were	performed	that	we	had	convincing	evidence	on	the	efficacy	of	the	
high	dose	1%	(ATOM1)	(Chua	et	al.	2006)	and	the	lower	doses	0.5,	0.1	and	0.01%	(ATOM2)	(Chia	et	
al.	2012)	atropine	in	slowing	childhood	myopia.		
A	Cochrane	review	of	the	interventions	to	control	myopia	progression	in	children	concluded	that	
atropine	was	the	only	treatment	showing	a	significant	efficacy	compared	to	placebo	(Walline	et	al.	
2011).		
Two	different	meta-analysis	(Huang	et	al.	2016;	Gong	et	al.	2017)	confirmed	the	conclusions	of	the	
Cochrane	review	showing	that	atropine	0.01%	have	comparable	efficacy	to	the	higher	dose	of	
atropine	with	the	advantage	of	a	lower	incidence	of	adverse	events	and	the	absence	of	rebound	
effect	after	discontinuing	the	treatment.	
Finally,	the	recent	report	of	American	Academy	of	Ophthalmology	states	that	level	I	evidence	
supports	the	use	of	atropine	for	the	control	of	myopia	progression	(Pineles	et	al.	2017).	
As	the	majority	of	the	studies	were	carried	out	with	Asian	descent	subjects,	few	data	are	available	
so	far	about	the	efficacy	of	atropine	in	slowing	myopia	in	European	population.		
Since	data	from	the	5	years	follow-up	of	the	ATOM2	study	(Chia	et	al.	2016)	were	available	
(September	2015),	we	started	to	treat	children	showing	progressive	myopia	with	a	daily	
application	of	atropine	0.01%.	This	retrospective	study	aimed	to	evaluate	the	efficacy	and	the	
safety	of	atropine	0.01%	in	slowing	myopia	progression	in	European	children	over	1	year	of	
treatment.		
MATERIALS	AND	METHODS	
We	conducted	a	retrospective	review	of	electronic	medical	records	of	children	referred	to	Eye	
Clinic,	San	Giuseppe	Hospital	(Milan,	Italy)	for	progressing	myopia	(>	0.50	D/year)	from	September	
2015	to	September	2016	and	treated	with	topical	atropine	0.01%.		
Criteria	for	inclusion	in	this	analysis	were:	patients	aged	5-16	years	with	a	myopic	progression	of	at	
least	0.5	D	in	the	past	year	(documented	by	cycloplegic	refractive	examinations),	treatment	with	
atropine	0.01%	once	in	the	evening	for	at	least	12	months,	best-corrected	visual	acuity	≥0.2	
(Snellen	acuity)	in	each	eye,	European	descent,	good	adherence	to	the	treatment	reported	by	the	
relatives	at	our	adherence	assessment	monitoring	(less	than	5	forgotten	doses/month).		Exclusion	
criteria	were:	myopia	related	to	collagen	and	systemic	syndromes,	and	myopia	due	to	
buphthalmos;	ocular	surgery	6	months	before	or	during	the	treatment	period;	the	use	of	
concomitant	ocular	medication	during	the	treatment	period;	a	diagnosis	of	developmental	
disorders	as	well	as	a	diagnosis	of	ocular	diseases,	such	as,	strabismus,	congenital	cataract,	
glaucoma,	corneal	opacity,	optic	neuropathy,	uveitis,	and	ocular	tumor;	previous	use	of	treatment	
with	a	potential	role	in	slowing	myopia	such	as	orthokeratology,	contact	lenses,	progressive	
addition	spectacle	lenses.	The	efficacy	was	evaluated	by	the	comparison	of	the	mean	change	in	
refractive	error	(spherical	equivalent,	SE,	assessed	under	cycloplegic	condition)	in	the	past	12	
months	before	treatment	with	the	12	months	after	atropine	treatment	was	started.		
We	included	in	the	analysis	a	control	group	of	myopic	children	with	SE	progression	>	0.5	D/year	
referred	to	our	Eye	Clinic	before	2015	and	meeting	the	inclusion	and	exclusion	criteria	of	the	
study,	except	that	they	have	not	been	treated	with	atropine.	Patients	with	a	follow-up	of	at	least	
two	years	were	considered	and	analyzed	as	a	control	group.	The	study	and	data	accumulation	
were	carried	out	with	approval	from	the	Institutional	Ethics	Committee	(San	Giuseppe	Hospital,	
MultiMedica)	and	adhered	to	the	tenets	of	the	Declaration	of	Helsinki.		
Study	design		
Every	patient	treated	with	atropine	routinely	received	a	complete	ophthalmic	examination	before	
treatment	and	6	and	12	months	after	initiation	of	treatment.	Distance	best	corrected	visual	acuity	
values	were	reported	in	decimal,	as	in	clinical	practice.	
Refractive	error	was	evaluated	under	cycloplegic	condition	at	baseline	and	12	months	after	
treatment	was	started	in	the	treated	group	and	at	12	months	interval	in	the	control	group	using	
Nikon	Retinomax	2	autorefractor	(Nikon,	Tokyo,	Japan).	The	same	device	has	been	used	
throughout	the	study	period.	The	SE	was	calculated	as	sphere	plus	+1/2	cylinder.	The	rate	of	
myopia	progression	was	calculated	by	subtracting	the	SE	at	baseline	from	the	SE	1	year	before	the	
treatment	(rate	of	progression	before	treatment)	and	SE	after	12	months	of	treatment	from	the	SE	
at	baseline	(rate	of	progression	during	treatment).	We	similarly	calculate	the	rate	of	progression	in	
the	control	group	throughout	24	months.	Treated	patients	were	considered	responders	if	SE	
progression	was	<	0.50	D	after	12	months	of	treatment	and	non-responders	if	SE	progression	
continued	even	under	atropine	use.	Adverse	events	were	assessed	during	the	examination.	Also,	
patients	and	parents	were	asked	for	any	adverse	events	eventually	occurred	during	the	treatment.	
The	same	pharmacy	compounded	all	eye	drops	bottles.	
Statistical	analysis	
Continuous	variables	were	expressed	as	mean	±	standard	deviation	(SD)	and	range	[min;	max].	
They	were	then	compared	between	treated	and	controls	by	using	the	T	test	(normally	distributed	
variables)	or	the	non-parametric	Wilcoxon	test	(not	normally	distributed	variables).	Differences	in	
myopic	progression	rate	were	evaluated	by	using	the	non-parametric	Wilcoxon	signed	rank	test.	
All	statistical	analyses	were	performed	by	using	SAS	Software	9.4.	Statistical	significance	was	set	to	
the	conventional	p-value<0.05.	
RESULTS	
Patients		
Among	the	pediatric	patients	referred	to	Eye	Clinic	San	Giuseppe	Hospital	from	September	2015	
to	September	2016,	52	Caucasian	children	(27/52	male,	52%)	treated	with	atropine	met	the	
inclusion	criteria	and	were	included	in	the	analysis,	and	50	children	(26/50	male,	52%)	were	
included	in	the	control	group.	The	mean	age	was	9.7	±	2.3	years	(range	5-14	years)	and	12.1	±	2.9	
years	(range	6-16	years)	in	the	atropine	and	the	control	group	respectively.		
At	baseline,	the	mean	SE	was	3.0	±	2.23	D,	and	2.63	±	2.68	D	and	the	mean	best-corrected	
distance	visual	acuity	was	0.58	±	0.28	and	0.65	±	0.14	in	the	atropine	and	in	the	control	group,	
respectively.	Only	age	was	statistically	different	between	the	two	groups	(p-value<0.0001).	All	the	
other	demographic	characteristics	were	comparable	between	groups	(Table	1).	
Efficacy		
Table	2	shows	the	myopic	progression	rate	in	the	studied	subjects.	In	the	treated	group	the	mean	
rate	of	myopia	progression	was	significantly	lower	after	1	year	of	follow-up	if	compared	with	the	
mean	myopia	progression	rate	12	months	before	treatment	(-0,54	±	0,61	D	vs	-1,20	±	0,64	D;	p-
value<0.0001).	The	responders	patients	were	41,	(79%)	whereas	11	patients	(21%)	showed	a	
progression	>	0.50	D	despite	treatment.	Among	the	11	non-responders,	none	showed	high	myopia	
(>	6	D),	and	none	were	less	than	6	years	old	at	baseline	(mean	SE	3,24	±	1,32;	mean	age	9,0	±	2,34,	
results	not	shown).	The	small	sample	size	of	these	subgroups	did	not	allow	a	statistical	analysis	of	
these	data.		
In	the	control	group,	untreated	subjects	showed	a	significantly	faster	progression	compared	to	
patients	using	atropine.	The	mean	rate	of	progression	during	the	first	and	the	second	year	of	
follow-up	was	-0,80	±	0,38	D	and	-1,09	±	0,64	D;	the	mean	rate	of	progression	in	the	control	
subjects	through	the	second	year	was	significantly	higher	if	compared	to	those	of	patients	treated	
with	atropine	(-1.09	D	vs	0.54	D,	p-value<0.0001).	The	final	mean	best-corrected	distance	visual	
acuity	was	0.81	±	0.2	in	the	treated	subjects	and	0.70	±	0.21	in	the	control	group.			
Safety		
Among	52	patients	receiving	atropine	5	patients	(9.6%)	complained	of	photophobia,	nevertheless,	
these	symptoms	were	temporary	and	not	severe	enough	to	warrant	discontinuing	treatment.	The	
use	of	atropine	was	overall	very	well	tolerated.	None	of	the	treated	patients	needed	
photochromatic	progressive	glasses	or	single-vision	photochromatic	glasses.	No	systemic	adverse	
events	were	reported.		
DISCUSSION		
In	this	retrospective	study,	we	investigated	the	efficacy	of	atropine	0.01%	for	the	control	of	
progressive	myopia	in	European	children.	In	our	practice,	we	adhered	to	the	indication	of	the	
ATOM2	study	(Chia	et	al.	2012)	(we	only	extended	the	age	from	5	to	16	years),	so	we	can	consider	
this	study	as	the	first	report	on	the	application	of	the	ATOM2	study	protocol	in	myopic	European	
children.	Similarly	to	the	ATOM2	study,	we	compared	the	mean	SE	change	before	and	after	
treatment	with	atropine.	The	rate	of	myopia	progression	after	12	months	of	daily	use	of	atropine	
was	significantly	lower	compared	to	the	rate	of	progression	before	starting	the	treatment.		
The	0.54	D	of	myopia	progression	in	the	treatment	period	in	our	study	was	similar	to	the	0.42	D	of	
progression	reported	after	the	12	months	of	atropine	in	the	ATOM2	study	(Chia	et	al.	2012).	In	
agreement	with	other	reports,	we	noted	that	a	percentage	of	patients	(21%)	showed	progression	
despite	treatment	with	atropine.	This	result	is	close	to	the	24%	of	progressing	patients	in	the	
0.01%	group	of	the	ATOM2	study.	It	has	been	reported	that	some	patients	seem	to	be	non-
responder	to	a	low-dose	of	atropine	(Chia	et	al.	2012;	Clark	&	Clark	2015).	In	these	non-responder	
patients	an	approach	with	a	higher	dose	of	atropine	should	be	balanced	with	potential	side	effects	
and	considered.															
We	introduce	a	control	group	of	patients	with	progressive	myopia	referred	to	our	Clinic	before	the	
routine	use	of	atropine.	The	subjects	in	the	control	group	showed	a	slower	rate	of	myopia	
progression	at	baseline	compared	to	the	atropine	group.	This	could	be	partially	explained	as	
subjects	in	control	group	are	slightly	older,	and	it	is	known	that	myopia	tends	to	decrease	its	
progression	in	children	of	older	age,	together	with	the	slightly	lower	percentage	of	subjects	with	
high	myopia	in	the	control	group.	It	is	worth	to	note	that	despite	the	faster	baseline	progression,	
the	treated	subjects	during	the	12	months	of	treatment	showed	a	significantly	slower	progression	
when	compared	to	the	progression	throughout	both	the	first	and	the	second	year	of	follow-up	in	
the	control	group.	
The	first	attempts	to	prevent	myopia	progression	using	atropine	date	back	to	the	60’s	(Otsuka	J	
1967),	and	first	randomized	clinical	trials	started	in	the	late	80’	(Yen	et	al.	1989;	Shih	et	al.	1999;	
Shih	et	al.	2001).	However	only	with	the	publication	of	the	ATOM1	study	the	role	of	the	atropine	
was	fully	elucidated.	This	randomized	trial	published	in	2006	involved	400	Chinese	children	and	
confirmed	that	atropine	is	a	powerful	tool	to	control	myopia	with	treated	subjects	showing	a	77%	
decrease	in	the	mean	progression	of	myopia	compared	to	placebo	(Chua	et	al.	2006).	The	first	
studies	(Yen	et	al.	1989;	Shih	et	al.	1999;	Shih	et	al.	2001),	as	well	as	the	ATOM1	study	(Chua	et	al.	
2006),	used	atropine	at	the	dose	of	1%.	At	that	concentration	atropine	has	been	shown	to	be	
effective	in	slowing	myopia	progression	(Chua	et	al.	2006),	however,	glare,	photophobia	and	near	
reading	difficulty	were	frequently	reported	(Chua	et	al.	2006;	Yi	et	al.	2015),	and	limited	a	wide	
diffusion	in	clinical	practice.	In	order	to	minimize	clinical	symptoms	lower	doses	of	atropine	have	
been	explored	from	0.5%	to	0.01%	(Chia	et	al.	2012).	The	ATOM2	study	was	the	first	study	
exploring	the	efficacy	of	atropine	0.01%	(Chia	et	al.	2012).	The	5-years	report	of	the	ATOM2	study	
showed	that	0.01%	dose	had	a	similar	efficacy	in	slowing	myopia	progression	compared	to	0.1%	
and	0.5%	over	24	months	of	treatment	(phase	1	of	the	ATOM2	study),	with	the	advantage	of	
significant	reduction	of	side	effects	associated	to	pupil	dilation	and	loss	of	accommodation	(Chia	
et	al.	2016).	In	addition	patients	treated	with	atropine	0.01%	did	not	show	the	rebound	effect	in	
the	wash-out	period	(phase	2	of	the	ATOM2	study)	like	patients	treated	with	atropine	0.1%	and	
0.5%.	In	the	phase	3	(retreatment	of	progressing	patients	with	0.01%)	of	the	ATOM2	study	only	
24%	of	patients	previously	treated	with	atropine	0.01%	needed	retreatment	compared	to	59%	and	
68%	in	the	0.1%	and	in	the	0.5%	group	respectively,	meaning	that	a	significantly	less	proportion	of	
patients	were	progressed	in	the	0.01%	group.	The	conclusion	of	the	5	years	report	of	the	ATOM2	
study	was	that	atropine	0.01%	was	significantly	more	effective	in	slowing	myopia	progression	with	
less	visual	side	effects	compared	to	0.1%	and	0.5%	dose	(Chia	et	al.	2016).																																								
To	date,	few	studies	investigated	the	efficacy	of	atropine	in	non-Asian	subjects	(Clark	&	Clark	
2015;	Polling	et	al.	2016;	Diaz-Llopis	&	Pinazo-Durán	2018)	and	only	two	of	them	with	atropine	
0.01%	(Clark	&	Clark	2015;	Diaz-Llopis	&	Pinazo-Durán	2018).	
In	the	study	of	Polling	and	coauthors,	atropine	was	used	at	the	higher	concentration	of	0.5%.	
Although	myopia	was	adequately	controlled,	the	frequency	of	adverse	events	was	relevant	with	
photophobia	reported	in	72%	of	subjects	(Polling	et	al.	2016).		
The	study	by	Clark	and	coauthors	was	the	first	study	analyzing	the	efficacy	of	atropine	0.01%	in	a	
subgroup	of	non-Asian	subjects	(Clark	&	Clark	2015).	The	study	was	conducted	in	the	United	States	
and	included	56	children	of	different	ancestry	(Asian,	Caucasian,	Hispanic,	and	African	American).	
In	this	retrospective	work	children	treated	with	atropine	0.01%	were	compared	with	a	control	
group.	The	Caucasian	patients	were	15	(54%	of	the	28	treated	patients).	One	significant	difference	
between	this	study	and	our	work	is	that	in	the	former	cycloplegic	refraction	was	not	routinely	
performed	and	change	of	SE	was	calculated	based	on	noncycloplegic	manifest	refraction.	Other	
difference	is	the	larger	sample	size	of	our	study,	including	52	Caucasian	treated	patients	(Clark	&	
Clark	2015).		
The	second	work	on	the	efficacy	of	atropine	0.01%	in	a	Caucasian	population	is	a	recently	
published	randomized	Spanish	study	comparing	the	rate	of	myopia	progression	of	100	treated	
patients	with	100	untreated	subjects	(Diaz-Llopis	&	Pinazo-Durán	2018).	In	this	study	atropine	
significantly	slower	myopia	progression	compared	to	control	group	(−0,14	±	0,35		vs	−0,65	±	0,54,	
respectively)	
There	are	some	differences	between	this	study	and	our	work.	Patients	in	the	Spanish	study	were	
older	compared	to	the	current	study	as	inclusion	age	was	9-12	years.	Inclusion	criteria	of	study	by	
Diaz-Llopis	and	colleague	were	similar	to	the	ATOM	1	study	(Chua	et	al.	2006),	as	children	with	
myopia	from	-0.50	to	-2.00	D	were	included	regardless	of	the	rate	of	progression.	In	our	study,	we	
included	children	with	progressive	myopia,	accordingly	with	the	ATOM	2	study	criteria	(Chia	et	al.	
2012).	Another	difference	to	be	commented	is	that	in	work	by	Diaz-Llopis	and	colleague	(Diaz-
Llopis	&	Pinazo-Durán	2018)	there	was	a	high	rate	of	drop	out	in	the	treatment	group	(53.5%),	so	
authors	upgraded	the	number	of	included	children	during	the	follow-up,	trying	to	balance	the	two	
group	by	“dynamic	randomization.”	This	may	have	biased	the	inclusion	process	and	the	final	
results	of	the	study.		
Atropine	is	a	non-selective	muscarinic	receptor	antagonist.	The	exact	mechanism	by	means	
atropine	would	arrest	myopia	is	not	clearly	understood	so	far.	In	animal	models,	atropine	showed	
to	prevent	the	development	of	myopia	effectively	(Schwahn	et	al.	2000;	McBrien	et	al.	1993).	A	
block	of	accommodation	has	been	postulated,	however,	atropine	was	able	to	prevent	myopia	
even	in	animals	that	do	not	have	accommodation	mechanism	(Saw	et	al.	2002).	In	addition,	
striated	ciliary	muscles	of	animals	like	chickens	showed	nicotinic	acetylcholine	receptors	rather	
than	muscarinic	receptor,	so	in	these	animals,	the	block	of	the	muscarinic	receptor	by	atropine	
would	not	be	useful	to	inhibit	accommodation	(McBrien	et	al.	1993).	Diether	et	coauthors	recently	
proved	that	atropine	could	inhibit	the	development	of	experimental	myopia	in	chickens	in	a	dose-
dependent	fashion.	Although	the	exact	mechanism	is	unknown,	findings	of	this	study	suggest	that	
atropine	seems	to	inhibit	the	synthesis	of	glycosaminoglycans	in	scleral	chondrocytes,	suggesting	
that	the	scleral	tissue	could	be	the	target	of	atropine	(Diether	et	al.	2007).	Among	the	limitations	
of	this	work	the	retrospective	design	of	the	study	carries	the	attendant	limitations	of	any	
retrospective	analysis	and	do	not	allow	an	evaluation	of	the	safety	of	the	drug	as	accurate	as	in	a	
clinical	trial,	however,	adverse	events	were	recorded	in	the	medical	charts	and	had	been	analyzed	
in	our	report.	The	9.6%	of	patients	complaining	of	transient	photophobia	is	close	to	the	6.3%	of	
photophobia	reported	in	a	recent	meta-analysis	(Gong	et	al.	2017)	and	was	the	only	adverse	event	
reported	by	the	treated	patient.	The	axial	length	was	not	analyzed.	Randomized	clinical	trial	as	the	
ATOM1	and	ATOM2	studies	(Chua	et	al.	2006;	Chia	et	al.	2012)	reported	axial	length	and	
suggested	that	the	control	of	myopia	progression	seems	to	depend	on	slowing	in	axial	growth.	The	
retrospective	nature	of	this	study	reflects	the	real-life	clinical	practice.	As	this	measurement	is	not	
routinely	performed	during	clinical	examination,	axial	length	data	are	lacking	in	our	analysis.	
Moreover,	differently	from	clinical	trials,	we	did	not	have	any	effective	method	to	control	
adherence	to	the	therapy;	nevertheless,	only	patients	with	less	than	5	forgotten	doses/month	
were	included	in	the	analysis.	This	study	did	not	include	patients	older	than	16	years.	Further	
studies	might	address	the	efficacy	of	low-dose	atropine	even	in	patients	in	the	late	teens	with	
progressive	myopia.	As	this	retrospective	chart	review	study	analyzed	patients	who	were	still	
under	treatment	with	atropine,	this	work	cannot	provide	information	about	the	myopia	
progression	after	cessation	of	treatment.	Further	analysis	will	elucidate	about	the	rebound	effect	
in	European	children	treated	with	low-dose	atropine.	Finally,	our	study	population	was	a	relatively	
homogeneous	group	of	European	children	aged	5-16	years	with	a	rate	of	progression	of	0.5D	of	SE	
in	the	past	year,	without	any	other	ocular	or	systemic	relevant	disease,	so	the	interpretation	of	
our	findings	should	be	restricted	to	similar	patients.				
Open	questions	remain	about	the	optimal	time	of	starting	and	cessation	treatment,	as	well	as	the	
approach	for	patients	still	progressing	under	atropine	0.01%	and	we	hope	this	study	will	
encourage	further	research	on	this	topic	and	these	open	issues.		
Besides	growing	literature	recently	is	debating	about	the	role	of	outdoor	time	in	the	control	of	the	
myopia	process,	suggesting	that	spending	time	in	outdoor	activities	may	play	a	role	in	slowing	
myopia	process,	so	future	studies	should	integrate	and	consider	the	role	of	outdoor	time	in	
combination	with	treatment	such	as	atropine	(Rose	et	al.	2008;	He	et	al.	2015;	Ramamurthy	et	al.	
2015).		
In	conclusion,	atropine	can	be	considered	the	only	approach	for	the	control	of	myopia	currently	
evidence-based.	Large,	randomized	studies	(Chua	et	al.	2006;	Chia	et	al.	2012)	and	recent	meta-
analysis	(Walline	et	al.	2011;	Huang	et	al.	2016;	Gong	et	al.	2017;	Pineles	et	al.	2017)	have	
demonstrated	that	daily	use	of	topical	atropine	can	prevent	further	myopia	progression	in	children	
and	pooled	evidence	suggests	that	the	low-dose	atropine	0.01%	is	effective	as	higher	atropine	
concentration	with	a	more	favorable	safety	profile.		
As	our	current	knowledge	on	the	efficacy	of	atropine	0.01%	is	substantially	based	on	data	coming	
from	Asian	subjects	(Chua	et	al.	2006;	Chia	et	al.	2012),	and	as	a	difference	in	efficacy	between	
White	and	Asian	people	has	been	postulated	(Li		et	al.	2014),	we	think	that	our	findings	on	the	
efficacy	of	low-dose	atropine	in	European	descent	children	could	be	of	clinical	interest.	This	study	
highline	as	even	in	European	patient	low-dose	atropine	is	an	effective	and	safe	treatment	and	
should	be	considered	in	myopic	subjects	meeting	the	inclusion	criteria	of	our	work.	
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